October 3, 2014

DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding

April 22, 2013

DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody

February 26, 2013

DecImmune Therapeutics Secures $2.25 Million in Development Funding

September 27, 2010

DecImmune Therapeutics Secures $3.2 Million in Development Funding